Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3^rd through October 5^th.

This year’s Virtual Annual Meeting remains one of the largest scientific symposiums focused on the field of transfusion medicine. Scientists and clinicians from around the globe will share the latest research and practice-changing resources in the fields of blood and biotherapies. Highlights from this year’s agenda include COVID-19-related research, and insights from AABB’s Standards Committee chairs on the new and revised standards and guidances impacting global blood safety.

“This is a hallmark event for Cerus and we look forward to connecting with our colleagues in the global transfusion medicine community,” said Dr. Richard Benjamin, Cerus’ chief medical officer. “Despite being virtual due to COVID-19, we are excited to present the latest clinical data supporting the use of INTERCEPT-treated blood components from Cerus and our scientific collaborators. This year, we will have 17 abstracts, including one oral presentation,” Benjamin continued.

“With the FDA Guidance for Industry on Bacterial Risk Control Strategies for Platelets six months away (March 31, 2021), Cerus will present several abstracts on this topic, including one focused on the economic aspects of INTERCEPT implementation in blood centers and hospitals,” Benjamin said. “As we near this important milestone in the U.S., we are focused on providing the data most valuable to the transfusion community,” he continued.

Currently, the major blood centers in the U.S. are moving ahead with broad roll-out of the INTERCEPT Blood System to meet the guidance.

A full list of abstracts from Cerus is available to view at:
https://intercept-usa.com/aabb2020

The Cerus oral presentation, entitled, “Optimizing U.S. Platelet Supply by Shifting Minimum Platelet Dose” will be presented on October 3rd at 7:15 p.m./EST.

Excerpts from select Cerus abstracts this year include:

• Optimizing US Platelet Supply by Shifting Minimum Platelet Dose, Travis Berry, Meredith Lummer
  The inclusion of lower minimum dose platelet products enables blood centers to increase platelet component availability while implementing FDA Bacterial Guidance strategies.
• Optimizing Platelet Availability and Access to a ~100% Pathogen Reduced Inventory, Tracy Collier, Vera Chrebtow, Patricia Schmidt
  A blood center’s experience with decreased platelet expiry resulting in $120,000 in savings per year when converting to a 100% pathogen reduced platelet inventory.
• Costs and Reimbursements for Bacterial Risk Control Strategies for Platelets: Results from a Hospital Budget Impact Model, Katherine M. Prioli, Jay H. Herman, Laura T. Pizzi
  Comparable net budget impact is shown between pathogen reduced and large volume delayed sample tested platelet products with a hospital budget impact model.
• In Vitro Evaluation of Platelets Stored for 7 Days Prepared with INTERCEPT Blood System, Jamie R. Genthe, Waseem Anani, Jose A. Cancelas, et al.
  In vitro study demonstrates retained metabolic and functional properties of INTERCEPT-treated platelet components stored for 7 days. (The INTERCEPT Blood System for 7-day storage of platelets is not approved in the US. Clinical trials are in progress: ClinicalTrials.gov Identifier: NCT04022889.)
• Efficient Inactivation of SARS-CoV-2 in Human Plasma with Amotosalen and Ultraviolet A Light Treatment, Esam I. Azhar, Salwa I. Hindawi, et al.
  Complete inactivation of SARS-CoV-2 was observed with INTERCEPT treatment of spiked plasma units. INTERCEPT may be effective in minimizing transfusion-transmitted infections of SARS-CoV-2.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Based in Concord, California, our employees are dedicated to deploying and supplying vital technologies and pathogen-protected blood components for blood centers, hospitals and ultimately patients who rely on safe blood. With the INTERCEPT Blood System, we are focused on protecting patients by delivering the full complement of reliable products and expertise for transfusion medicine. Cerus develops and markets the INTERCEPT Blood System and remains the only company in the blood transfusion space to earn both CE Mark and FDA approval for pathogen reduction of both platelet and plasma components. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.